Johnson & Johnson's Dual-Target CAR-T Therapy JNJ-90014496 Demonstrates Impressive Efficacy in Relapsed/Refractory LBCL

Jul 15, 2025 08:37 CST Updated 08:37

Johnson & Johnson

Medical Device R&D and Manufacturer

Johnson & Johnson asMMThe leader in the field has almost monopolized the relevant therapies in this area, but Johnson & Johnson is not satisfied with the status quo and has begun to expand into other hematological tumors.2023Year5Month2Day,Johnson & Johnson andCBMG Reaches Global Exclusive Cooperation to Jointly Develop and Commercialize Next-Generation NovelCAR-TCell Therapy ProductsC-CAR039(TargetedCD19/CD20) andC-CAR066（TargetedCD20), used for the treatment of non-Hodgkin lymphoma(NHL)。In this year'sEHAAt the meeting, Johnson & Johnson disclosedJNJ-90014496（C-CAR039) TreatmentR/R LBCLClinical data.

C-CAR039For the new second generation4-1BBDual-targetCAR-TProducts that can act simultaneously onCD19AndCD20Dual targets, can continuously clear in vivoCD19/CD20Single-positive or double-positive tumor cells. In China,C-CAR039InLBCLIn the treatment of,4The annual follow-up results showed a complete remission rateCRFor86%，4Year'sOSFor67%，4Year'sPFSFor53%。

Johnson & Johnson's disclosure this time isC-CAR039TreatmentR/R LBCLGlobal1bPhase Clinical Study, Globally8Country31A total of clinical centers recruited51Conduct research on different doses and drug efficacy for patients.The three dose groups are respectively2 M(Million)/kg，150 MAnd75 M, and it has been confirmed so far75 MForRP2DDose。

Baseline of enrolled patients is as follows:All51Approximately among the patients73%ForDLBCL NOS,And inRP2DIn the group, there20%The patients have receivedCD20Targeted therapy,8%The patient has receivedCD19Targeted Therapy（R07227166AndRO7443904). In addition, inRP2DIn the group,48%Patients who have previously received1Line therapy,52%Patients who have previously received ≥2Line therapy.

In terms of safety,All patients experienced treatment-related side effects, among which inRP2DIn the dosage group,84%Patients experience3-4Grade side effects, with the main side effect being neutropenia,CRS，Thrombocytopenia, anemia, fatigue, diarrhea, infection, etc. ForCRSSide effects,RP2DIn the dose group88%The incidence rate, but all are1~2Level

Neurotoxicity，16%Occurred in patientsICANSSide effects, among which8%For3Level reaction; and inRP2DIn the dose group8%Patients experienceICANSSide effects, including4%For3Grade reaction.

In terms of efficacy: All patients,OverallORRFor91%, among which75%of patients reachedCR, and inRP2DIn the dose group, overallORRFor100%, among which77%of patients reachedCR.RP2DFurther analysis of the treatment effects in the dose group patients who had previously received1Among patients undergoing line therapy, overallORRFor100%，CRRate is80%, and have received ≥2Among patients receiving line therapy,ORRFor92%，CRFor75%。

By contrast, let's take a look at several products that have already been launched.CAR-TTherapy inDLBCLTherapies in China, overall theirCRRate in40%~58%Between, and in terms of neurotoxicity,JNJ-90014496Also has certain advantages, with an overall incidence rate of8%, The incidence rate of Grade III is4%。

The overall incidence of ICANS with Kymriah was 11%, not the grade 3 incidence.

Summary

JNJ-90014496（C-CAR039) Simultaneously targeting CD19 and CD20 can theoretically prevent resistance caused by the loss of the CD19 target, and in clinical practice, it has advantages over traditional CAR-T therapy.It also showcasedGood safety and better efficacy. In China,A four-year follow-up by Cibiem also showedThe therapy in relapse/Refractory (R/R) LargeBCellular Lymphoma (LBCL) Long-term survival benefits in patients.

Scan the WeChat QR code, add the editor of the Antibody Circle, and those who meet the requirements can join the Antibody Circle WeChat group!

Please indicate: Name + Research Direction!

All articles reprinted by this official account are intended to convey more information, with the source and author clearly stated. Media or individuals who do not wish to be reprinted can contact us (cbplib@163.com), and we will immediately delete the content. All articles represent the views of the author and do not represent the position of this site.